The US FDA study is intended to evaluate the system for treating life-threatening ventricular tachyarrhythmias.

Background: Because the natural history of atrial tachyarrhythmia (AT) is not known in patients with implantable cardioverter-defibrillators (ICDs) but without device-based atrial therapies, we aimed ...

Researchers report favorable safety and efficacy for a combination device after implantation and at 6 months follow-up among ...

"Appropriately selected patients with NICM have the potential to benefit from primary prevention ICD therapy…Besides consideration of ICD placement, attention to guideline-directed medical therapy and ...